Polatuzumab vedotin
Polivy · Antibody-drug conjugate (CD79b/MMAE)
Tumor lysis; emerging renal data.
Antibody-drug conjugate (CD30/MMAE)
Adcetris · BV
Antibody-drug conjugate (CD30/MMAE) · approved 2011 · 5 citations · FAERS AKI reporting ROR 1.91 (95% CI 1.67–2.19, 208 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A CD30/MMAE conjugate whose main renal risk is tumor lysis in bulky lymphoma — direct nephrotoxicity is minimal.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is minimal. Tumor lysis syndrome occurs at low rates (<=5% in anaplastic large-cell lymphoma experience) and is the principal pathway to AKI/electrolyte disturbance; renal-specific incidence is not quantified.Source: Howard et al., Ann Hematol 2016 (systematic review)
Early — tumor lysis in the first cycle(s) of bulky disease.
Distilled from: “Early — tumor lysis in the first cycle(s) of bulky disease.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Tumor lysis syndrome (incidence <=5% in ALCL trials) is the principal indirect pathway to AKI; direct nephrotoxicity is minimal
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Tap a signature to trace where it strikes the nephron.
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Antibody-drug conjugate targeting CD30 and delivering MMAE via a protease-cleavable linker, causing microtubule disruption and apoptosis in CD30+ tumor cells. Approved for Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and other CD30-expressing lymphomas.
Class-level context for the major non-renal toxicities of the Antibody-drug conjugate (CD30/MMAE) class.
Hematologic
Cytopenias, thrombosis, TMA
Ophthalmic
Keratopathy, uveitis, retinopathy
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
4 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Quoted verbatim from this agent's current FDA label (Nov 2025) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS [see Warnings and Precautions (5.9) , Adverse Reactions (6.1) ] . WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) See full prescribing information for complete boxed warning. JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS ( 5.9 , 6.1 ).
Renal impairment — from the label
Avoid the use of ADCETRIS in patients with severe renal impairment (CrCL <30 mL/min) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3) ]. No dosage adjustment is required for mild (CrCL >50–80 mL/min) or moderate (CrCL 30–50 mL/min) renal impairment.
Kidney rows of the label's dosage tables
From the ADCETRIS label (Nov 2025) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 10,402 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,994 of 10,402 reports
Reported with hospitalization
3,931 of 10,402 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 643 of the 10,402 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Brentuximab vedotin sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Polivy · Antibody-drug conjugate (CD79b/MMAE)
Tumor lysis; emerging renal data.
Mylotarg · Antibody-drug conjugate (CD33/calicheamicin)
Tumor lysis and veno-occlusive disease.
Besponsa · Antibody-drug conjugate (CD22/calicheamicin)
Tumor lysis and VOD in ALL.
Brukinsa · BTK inhibitor
Tumor lysis in CLL/lymphoma.
Epkinly · Bispecific (CD20×CD3)
CRS and tumor lysis — emerging.
Columvi · Bispecific (CD20×CD3)
CRS and tumor lysis — emerging.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Brentuximab vedotin’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Brentuximab vedotin; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 11 clinical records among all 13 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.